ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 570,20
0,00%
Dow Jones
38 834,86
0,15%
DAX
18 067,91
-0,31%
Brent Oil
84,555
-0,17%
Bitcoin
65 582,80
0,95%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. uniQure NV (QURE)

  7. uniQure NV (QURE) Actualités

QURE uniQure NV

4,57
-0,12 (-2,56%)
19 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
uniQure NV QURE NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,12 -2,56% 4,57 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
4,65 4,515 4,67 4,57 4,69
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
18/6/202401:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/6/202401:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/6/202401:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/6/202401:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/6/202400:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202413:18EDGAR2Form 8-K - Current report
03/6/202413:05GLOBEuniQure Receives FDA Regenerative Medicine Advanced Therapy..
07/5/202414:03EDGAR2Form 8-K - Current report
07/5/202413:57EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202413:05GLOBEuniQure Announces First Quarter 2024 Financial Results and..
05/3/202423:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202414:29EDGAR2Form S-8 - Securities to be offered to employees in employee..
28/2/202414:00EDGAR2Form 8-K - Current report
28/2/202413:05GLOBEuniQure Announces 2023 Financial Results and Highlights..
26/2/202422:46EDGAR2Form 144 - Report of proposed sale of securities
26/2/202422:25EDGAR2Form 144 - Report of proposed sale of securities
13/2/202422:33EDGAR2Form SC 13G - Statement of acquisition of beneficial..
19/12/202313:12EDGAR2Form 8-K - Current report
19/12/202313:05GLOBEuniQure Announces Update on Phase I/II Clinical Trials of..
12/12/202301:30PRNUSCSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb)..
08/12/202313:05GLOBEuniQure Announces Inducement Grants Under Nasdaq Listing..
29/11/202313:05GLOBEuniQure Announces FDA Clearance of Investigational New Drug..
17/11/202312:00EDGAR2Form 8-K - Current report
07/11/202313:52EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:31EDGAR2Form 8-K - Current report
07/11/202313:05GLOBEuniQure Announces Third Quarter 2023 Financial Results and..
27/10/202316:00PRNUSCSL and uniQure Win 2023 Prix Galien USA Award
26/10/202320:38PRNCASanté Canada autorise HEMGENIX® de CSL (étranacogène..
26/10/202320:14PRNCAHealth Canada Authorizes CSL's HEMGENIX® (etranacogene..
24/10/202313:05GLOBEuniQure Announces Major Presence at the European Society of..
06/10/202312:33EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
06/10/202312:32EDGAR2Form DEF 14A - Other definitive proxy statements
05/10/202322:32EDGAR2Form 8-K - Current report
05/10/202313:05GLOBEuniQure Announces Strategic Reorganization to Reduce..
03/10/202303:50EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/10/202313:05GLOBEuniQure Announces Inducement Grants Under Nasdaq Listing..
20/9/202322:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202319:59DJNRe/Max, UniQure and Trinseo Fall to 52-Week Lows on Exit..
05/9/202313:05GLOBEuniQure Announces FDA Clearance of Investigational New Drug..
02/9/202300:51PRNUSBlackstone and Airbnb Set to Join S&P 500; Others to Join..
01/8/202322:30EDGAR2Form 8-K - Current report
01/8/202313:37EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202313:05GLOBEuniQure Announces Second Quarter 2023 Financial Results and..
12/7/202322:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/7/202316:58EDGAR2Form 144 - Report of proposed sale of securities
26/6/202313:11GLOBEuniQure Announces Leadership Addition to Support Advancement..

Dernières Valeurs Consultées

NASDAQ
QURE
uniQure NV
UNSW3
KINEETH
Kine Governance Token
BOV
GGBR3F
GERDAU ON
NYSE
HYY
Strd 6.25 Verizon
ASX
TAT
Tartana Minerals
NASDAQ
PONOU
Pono Capital
BIT
P1X500
NLBNPIT1X500 20351221 23...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés